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ABSTRACT
Background: Rosuvastatin has been reported to be beneficial in the treatment 
of dyslipidemia. The Cmax and AUC0–t of rosuvastatin were reported to be ~2 to
4 times higher in Chinese subjects compared with white subjects after administration
of a single 1-mg/kg dose. 
Objectives: The aims of this study were to assess the pharmacokinetics and 
tolerability of multiple doses of rosuvastatin in healthy Chinese volunteers.
Methods: This open-label, randomized-sequence, 3-way crossover trial con-
sisted of three 7-day treatment periods and two 10-day washout periods. Healthy 
volunteers were randomly allocated to 1 of 3 daily treatment regimens: rosuvastatin 
5, 10, or 20 mg. To assess the pharmacokinetics and tolerability of rosuvastatin, blood
samples were drawn before dosing (hour 0) on days 5, 6, and 7 and 0.5, 1, 1.5, 2, 3,
4, 5, 6, 8, 12, 15, 24, 36, 48, 72, and 96 hours after the final dose was administered
on day 7. A validated HPLC-MS/MS method was used to determine rosuvastatin lev-
els. A 2-compartment pharmacokinetic model was fitted to the plasma concentration–
time profiles obtained for each volunteer. Adverse events (AEs) were monitored
throughout the study via subject interview, vital signs, and blood sampling. Serious
AEs were those requiring hospitalization, treatment discontinuation, or resulting in
death.
Results: Twelve healthy Chinese volunteers (6 men: mean [SD] age,
21.8 [1.7] years; weight, 62.3 [5.8] kg; height, 174.3 [7.2] cm; 6 women: age, 
20.8 [1.2] years; weight, 53.2 [4.7] kg; height, 161.3 [4.3] cm) participated in and
completed the trial. The mean (SD) steady-state Cmax was significantly greater after ro-
suvastatin administration in the 20-mg group compared with the 5-mg group (37.69 
[29.83] vs 6.17 [6.03] ng/mL; P = 0.04). The t1/2 was significantly greater in the 20-mg
group (15.51 [6.43] hours) compared with the 5-mg group (5.65 [5.08] hours; P =
0.001) and the 10-mg group (8.58 [5.17] hours; P = 0.002). The mean AUC0–t was
significantly greater in the 20-mg group compared with the 5-mg group (349.16 
[257.20] vs 40.63 [39.31] ng/mL/h; P = 0.02). All AEs were considered by the inves-
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tigators to be mild in intensity, with the exception of 2 cases of abdominal discomfort
(1 man and 1 woman, both in the 5-mg dose group). Two women in the 20-mg group
experienced dizziness and cold sweats simultaneously. In the 10-mg group, 1 woman
had abdominal discomfort and nausea and 1 woman had jaw pain.  All reported AEs
were considered possibly related to study drug administration.
Conclusions: In this small study in healthy Chinese volunteers, rosuvastatin 
systemic exposure appeared to be dose-proportional over the dosing range of 5 to 
20 mg with multiple-dose administration. There was no accumulation of rosuvastatin 
in the body with the 5- and 10-mg doses. However, the results suggest that rosuva-
statin might accumulate when the dose is increased to 20 mg. No serious AEs oc-
curred in any of the 3 dosing groups. (Curr Ther Res Clin Exp. 2009;70:392–404) © 
2009 Excerpta Medica Inc.
Key words: rosuvastatin, pharmacokinetics, multiple doses, tolerability, Chinese.
INTRODUCTION
Rosuvastatin has been reported to be beneficial in the treatment of dyslipidemia by
inhibiting 3-hydroxy-3-methyl-glutaryl coenzyme A reductase activity.1,2 In clinical
trials, rosuvastatin was associated with a reduction in serum LDL-C concentration, a
modest increase in serum HDL-C concentration, and a decrease in serum triglyceride
concentration.3–5
The pharmacokinetics of rosuvastatin have been reported in healthy white volun-
teers and Chinese subjects.6–13 In a trial of the pharmacokinetics of rosuvastatin after 
single-dose oral administration in Chinese volunteers, AUC and Cmax were reported
to be significantly lower when rosuvastatin 10 mg was administered in the fed versus
the fasting state.10 The Cmax and AUC0–t of rosuvastatin 1 mg/kg were found to be ~2
to 4 times higher in Chinese subjects compared with those of white subjects.10–14
Despite these findings in Chinese subjects, a search of MEDLINE (2001–2007; 
English and Chinese languages; search terms: rosuvastatin, pharmacokinetics) found no
report of the pharmacokinetics and tolerability of multiple-dose administration of 
rosuvastatin.
The primary end point of this study was to evaluate the pharmacokinetics of mul-
tiple doses of rosuvastatin in healthy Chinese volunteers. The secondary end point of 
the study was to evaluate the tolerability of the drug. 
SUBJECTS AND METHODS
Study Protocol and Subjects
The study protocol (2005L03371) was approved by the institutional review board 
of Sichuan University (Chengdu, China) before the study was conducted in August of 
2006. Before entering the study, all subjects provided written informed consent. 
Volunteers aged 20 to 25 years with a body mass index of 19 to 25 kg/m2 who were 
in good health were eligible for the study. Individuals were excluded if they had clini-
cally significant neoplastic, cardiovascular, hepatic, diabetic, renal, gastrointestinal,
metabolic, neurologic, pulmonary, endocrine, or psychiatric disease. Individuals were
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also excluded from the study if they were taking any drugs, using alcohol or cigarettes 
(no consumption within a week of enrollment), or had any other characteristic that
might confound the interpretation of the results or impair subject response.
Design and Clinical Procedure
This open-label, randomized-sequence, 3-way crossover study was conducted at 
the West China Second University Hospital (Sichuan, China). The study consisted
of three 7-day treatment periods and two 10-day washout periods (Figure 1). The 
10-day washout was chosen as a convenience to the volunteers. Volunteers were ran-
domly allocated using SPSS software version 10.0 (SPSS Inc., Chicago, Illinois) to 
receive rosuvastatin 5-, 10-, or 20-mg tablets (Jingxin Pharmaceutical Company, Ltd.,
Zhejiang, China) daily at 7:00 am under fasting conditions. Breakfast, lunch, and
dinner were given to all volunteers at predetermined times. Volunteers were ambula-
tory during the study but were asked to refrain from strenuous activity. They were
under direct medical supervision at the study site for 45 days.
Screening
(N = 18)
Randomization
(n = 12)
5 mg
(n = 2)
10 mg
(n = 2)
20 mg
(n = 2)
5 mg
(n = 2)
20 mg
(n = 2)
10 mg
(n = 2)
20 mg
(n = 2)
5 mg
(n = 2)
10 mg
(n = 2)
10 mg
(n = 2)
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(n = 2)
20 mg
(n = 2)
10 mg
(n = 2)
20 mg
(n = 2)
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(n = 2)
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Figure 1. Disposition of study subjects. The study comprised three 7-day treatment peri-
ods, each separated by a 10-day washout period.
395
R. Zhang et al.
Blood samples of ~4 mL were drawn via indwelling catheter (or via syringe when
blood clotting occurred) into heparinized tubes (Vacutainer, Becton, Dickinson and 
Company, Franklin Lakes, New Jersey) before dosing (hour 0) on days 5, 6, and 7, and
0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 15, 24, 36, 48, 72, and 96 hours after the final rosuva-
statin dose was administered on day 7. The blood samples were centrifuged at 1500g for
10 minutes at room temperature. Plasma was separated and kept frozen at –80°C in 
coded polypropylene tubes. Samples were analyzed at the Department of Clinical Phar-
macy and Pharmaceutical Administration, School of Pharmacy, Sichuan University,
Chengdu, Sichuan, China.
Materials
Estrone (purity 98%), which was used as the internal standard, was obtained from 
the Chinese National Institute for the Control of Pharmaceutical and Biological Prod-
ucts (Beijing, China). Methanol, glacial acetic acid, and formic acid were purchased
from Tedia Co., Inc. (Fairfield, Iowa) and tetrabutyl ammonium hydroxide (TAH) was 
purchased from Kalong Chemical (Chengdu, China). Ethyl acetate was obtained from
Ark Chemical (Chengdu, China). Water was obtained by distillation in glass and pas-
sage through a water purification system (Milli-Q Plus, Millipore, Bedford, Massa-
chusetts). Methanol, glacial acetic acid, and water were the appropriate grades for use
in HPLC. Ethyl acetate was analytically pure and redistilled; the other reagents were 
analytically pure.
Tolerability Assessments
Adverse events (AEs) were monitored throughout the study via subject interview, 
vital signs, and laboratory measurements. Rescue medications and first aid drugs
were available at the experiment site to ensure the volunteers’ safety. Physicians and 
nurses were present during the trial and judged which symptoms were study-drug
related. The laboratory profile, which included a clinical chemistry profile (creati-
nine, total bilirubin, direct bilirubin, alanine aminotransferase [ALT], aspartate 
aminotransferase, alkaline phosphatase, creatine kinase [CK]) and urinalysis (spe-
cific gravity, pH, protein, and plasma), was assessed before and after the study. A 
12-lead ECG was obtained at the beginning and completion of the study. Vital signs
(body temperature, blood pressure, and heart rate) were measured daily until the 
fifth day, after which blood was drawn daily. Axillary body temperature was mea-
sured using a thermometer (Diling Thermometer Company, Ltd., Jiangsu, China);
blood pressure and heart rate were measured electronically using a vital-signs moni-
tor (Panasonic Corporation of China, Beijing, China). Serious AEs were those requir-
ing hospitalization, treatment discontinuation, or resulting in death. 
Analysis of Samples
Preparation of Standard and Quality Control Samples
According to the method of Lan et al,15 the standard curve of rosuvastatin in hu-
man plasma is 0.1, 0.2, 0.5, 1, 2, 5, 10, 20, 50, and 100 ng/mL. The concentration
of internal standard in plasma was 100 ng/mL.
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Quality control (QC) samples were prepared on the day of analysis and in bulk at
4 concentrations: 0.1, 0.5, 10, and 50 ng/mL. The internal standard stock solution
was made up in methanol at a concentration of ~50 μg/mL and was stored at –20°C
and protected from light for ≤1 month. On the day of analysis, a dilution of this solu-
tion was prepared in methanol to a concentration of ~1000 ng/mL.
Sample Treatment
Control (blank) plasma was obtained from the Chengdu Blood Center (Chengdu,
China) for calibration, and bulk spiked QC samples were removed from the freezer and
allowed to thaw to room temperature (~4 hours) before extraction. Control plasma with a
volume of 1100 μL (1.0 mL of blank plasma spiked with 100 μL of working standard solu-
tions of various concentrations) and sample plasma with a volume of 1100 μL (1.0 mL of 
sample plasma added to 100 μL of 1 M acetic acid/methanol [50:50 v/v]) were prepared 
for extraction. Then, 100 μL of 0.5% acetic acid in water and 600 μL of 0.5% TAH in
water were added to form an ion pair with rosuvastatin; subsequently, 100 μL of internal 
standard working solution was added. A sample was extracted using 4 mL of ethyl acetate
in a vortex shaker (Vortex Genius 3, IKA-Werke GmbH & Co., Staufen, Germany). The
upper organic phase was transferred and evaporated to dryness under a stream of nitrogen 
at 40°C (N-EVAP 11155, Organomation Associates, Inc., Berlin, Massachusetts). The
residue was reconstituted in 200 μL of 0.5% acetic acid in water/methanol (50:50 v/v). The 
sample was transferred to the glass autosampler vial insert and 50 μL was injected into the
chromatographic system.
Chromatography and Mass Spectrometry
We used the same methods for analyzing rosuvastatin as those of Lan et al,15 as
conducted in our previous single-dose analysis of rosuvastatin.10
Pharmacokinetic and Statistical Analysis
The steady-state Cmax (Cssmax) and Tmax were observed visually from the plots of 
rosuvastatin plasma concentration versus time. All data were processed using DAS
software version 2.0 (Drug and Statistics, Anhui, China) to construct pharmacokinetic 
profiles. Accumulation factor is the ratio of the steady-state concentration to the concen-
tration after the first administration.
The primary data analysis included all study participants, and tolerability data were
summarized descriptively. The Newman-Keuls test was used to evaluate the differences in 
AUC0–t/dose, Cssmax/dose, and t1/2 among the 3 doses administered. The statistical signifi-
cance of t1/2, Cssmax, and AUC0–t between the male and female groups and the 2 forms of 
administration (single- and multiple-dose) was evaluated using the t test. The Wilcoxon 
rank sum test was used to analyze the differences in Tmax. P < 0.05 was considered statisti-
cally significant. A sample size calculation was not performed. 
RESULTS
Eighteen individuals were approached to enroll in the study, but 6 were excluded 
because they were currently administering drugs (n = 2) or they were smoking
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cigarettes (n = 4). Twelve healthy Chinese volunteers (6 men: mean [SD] age, 
21.8 [1.7] years; weight, 62.3 [5.8] kg; height, 174.3 [7.2] cm; 6 women: age,
20.8 [1.2] years; weight, 53.2 [4.7] kg; height, 161.3 [4.3] cm) were enrolled and
completed the trial (Table I).
Pharmacokinetics
The mean Cssmax and AUC0–t values were both linear in the range of doses admin-
istered. The mean (SD) Cssmax was significantly greater after rosuvastatin admin-
istration in the 20-mg group compared with the 5-mg group (37.69 [29.83] vs
6.17 [6.03] ng/mL; P = 0.04) (Figure 2). Tmax was similar in the rosuvastatin 5-, 10-, and
20-mg groups (3.17 [1.53], 2.96 [2.06], and 5.63 [9.76] hours, respectively) (Table II). 
The t1/2 was significantly greater in the 20-mg group (15.51 [6.43] hours) compared with
the 5-mg group (5.65 [5.08] hours; P = 0.001) and the 10-mg group (8.58 [5.17] hours; 
P = 0.002). The AUC0–t value after rosuvastatin administration was significantly greater 
in the 20-mg group compared with the 5-mg group (349.16 [257.20] vs 40.63 
[39.31] ng/mL/h; P = 0.02) (Table II). The accumulation factor was 1.07 (0.22), 1.00 (0),
and 3.13 (4.79) in the rosuvastatin 5-, 10-, and 20-mg groups, respectively (Table II).
Cssmax, Tmax, t1/2, and AUC0–t were compared between the male and female sub-
jects. For the 5-mg dose, Cssmax was significantly higher in the women compared with 
the men (7.29 [3.67] vs 3.00 [4.45] ng/mL; P = 0.02). With the 5-mg dose, Tmax was
significantly greater in the men than in the women (3.67 [1.21] vs 2.00 [0.71] hours; 
P = 0.04). No other significant differences were found in rosuvastatin pharmacokinet-
ics between the 2 groups (Table III).
Tolerability
No serious AEs occurred during the study. All AEs were considered by the inves-
tigators to be mild in intensity, with the exception of 2 cases of moderate abdomi-
nal discomfort (1 man and 1 woman, both with the 5-mg dose). Two women in the 
20-mg group experienced dizziness and cold sweats simultaneously, and were 
treated successfully with oral glucose. In the 10-mg group, 1 woman had abdominal
discomfort and nausea that resolved without treatment and one had jaw pain that
resolved after a 3-day regimen of amoxicillin 0.25 g TID (Table IV). The possibility of 
Table I. Baseline demographic characteristics of the study population
of healthy Chinese volunteers (N = 12). Data are mean (SD).
Characteristic Males (n = 6) Females (n = 6)
Age, y 21.8 (1.7) 20.8 (1.2)
Weight, kg 62.3 (5.8) 53.2 (4.7)*
Height, cm 174.3 (7.2) 161.3 (4.3)
BMI, kg/m2 20.5 (0.6) 20.4 (0.9)
BMI = body mass index.
*P < 0.001 versus males.
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acupuncture syncope could not be eliminated because blood samples were drawn via 
syringe instead of via the indwelling catheter in subjects who experienced blood clot-
ting. All reported AEs were considered possibly related to study drug administration.
Three subjects had an increased white blood cell count and serum CK and ALT 
levels ≥2 times the upper limit of normal on day 7 (Table V); none of the increases 
was considered clinically significant. Two and 3 subjects, respectively, had ALT and
CK >1 times upper limit of normal. One subject had simultaneous increases in ALT,
direct bilirubin, and CK. Another subject had simultaneous increases in total biliru-
bin, direct bilirubin, and CK. All subjects who had increased laboratory values recov-
ered without additional treatment.
DISCUSSION
The statistical differences in t1/2 between rosuvastatin 20 mg and the other doses 
were consistent with nonlinear dynamics. The long t1/2 and the large accumulation
factor with the 20-mg dose may have contributed to the saturation of some en-
zymes. The rosuvastatin absorption rate was considerably slower than its elimina-
tion rate, indicating that the drug may exhibit absorption rate–limited elimination
(flip-flop pharmacokinetics). The lower first-order absorption rate constant was re-
Table II. Pharmacokinetics of rosuvastatin in plasma in healthy Chinese volunteers
(N = 12). Values are mean (SD).
Rosuvastatin
Parameter 5 mg 10 mg 20 mg
Cssmax, ng/mL 6.17 (6.03)* 19.13 (18.96) 37.69 (29.83)
Cssmin, ng/mL 0.23 (0.25) 1.17 (1.30) 1.57 (1.33)
Css, ng/mL 1.67 (1.66) 5.78 (1.30) 11.48 (9.53)
DF 3.96 (1.54) 4.03 (5.68) 4.31 (2.76)
Tmax, h 3.17 (1.53) 2.96 (2.06) 5.63 (9.76)
ke, h 47.20 (91.76) 65.3 (5.19) 85.79 (81.96)
t1/2, h 5.65 (5.08)
† 8.58 (5.17)‡ 15.51 (6.43)
Ka, h 26.41 (89.44) 19.34 (5.40) 2.87 (2.72)
AUC0–t, ng/mL/h 40.63 (39.31)
§ 160.97 (55.21) 349.16 (257.20)
AUC0–∞, ng/mL/h 46.39 (53.27) 164.30 (151.06) 367.91 (245.36)
Accumulation factor 1.07 (0.22) 1.00 (0) 3.13 (4.79)
Cssmax = maximum plasma steady-state concentration; Cssmin = minimum plasma steady-state concen-
tration; Css = plasma steady-state concentration; DF = degree of fluctuation ([Cssmax – Cssmin]/Css); ke =
elimination rate constant; Ka = absorption rate constant.
*P = 0.04 versus rosuvastatin 20 mg.
†P = 0.001 versus rosuvastatin 20 mg.
‡P = 0.002 versus rosuvastatin 20 mg.
§P = 0.02 versus rosuvastatin 20 mg.
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Figure 2. Mean plasma concentration–time profiles in healthy Chinese volunteers administered multiple doses of rosuvastatin 5, 
10, and 20 mg (N = 12).
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Table III.  Pharmacokinetics of rosuvastatin in plasma in healthy male (n = 6) and female (n = 6) Chinese volunteers. Values are 
mean (SD).
Rosuvastatin
5 mg 10 mg 20 mg
Parameter Male Female Male Female Male Female
Cssmax, ng/mL 3.00 (4.45)
* 7.29 (3.67) 21.75 (22.80) 16.51 (15.95) 50.04 (29.00) 22.71 (31.44)
Tmax, h 3.67 (1.21)
† 2.00 (0.71) 3.83 (1.72) 2.08 (1.16) 2.40 (0.89) 3.25 (3.17)
t1/2, h 6.07 (5.57) 3.38 (2.42) 7.55 (2.30) 9.60 (2.50) 17.45 (6.80) 13.35 (6.67)
AUC0–t, ng/mL/h 19.57 (25.12) 48.51 (28.78) 199.28 (181.52) 122.66 (116.81) 418.65 (170.99) 278.63 (361.10)
Cssmax =  maximum plasma steady-state concentration.
*P = 0.02 versus females. 
†P = 0.04 versus females.
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sponsible for this phenomenon. The second peak in the plasma concentration–time
profile suggested enterohepatic circulation; elimination was slower with the 20-mg
dose compared with the 5- and 10-mg doses.
A statistically significant difference (P = 0.02) in Cssmax with the 5-mg dose was
found between the male and female groups. With the 5-mg dose, Tmax was signifi-
cantly greater in the men than in the women (3.67 [1.21] vs 2.00 [0.71] hours; P = 
0.04). However, sex had no influence on Tmax with the 10- or the 20-mg dose. Rosu-
vastatin metabolism may be different in men than in women, and metabolism may 
have been saturated with the 10- and 20-mg doses.
No statistically significant differences were found in the Tmax, AUC0–t, and 
Cmax between single- and multiple-dose administration.
10 With rosuvastatin 5 mg, 
the t1/2 with single-dose administration was significantly longer than that with 
multiple-dose administration. Sex had no influence on rosuvastatin pharmacoki-
netics in the single-dose study; however, in the multiple-dose study, significant
differences in the rate and degree of absorption were found between male and fe-
male subjects. These findings suggest that sex has an influence after prolonged 
administration. 
According to the pretesting, the steady-state concentration was achieved after
4 days of administration. The concentration was less than one twentieth of Cssmax
and most of the increased laboratory findings occurred 96 hours after the end of 
the 7-day drug administration period. Blood samples were collected beginning on
day 5, and all laboratory values were monitored for 96 hours after the treatment 
period.
This study had several limitations. The small study population, open-label de-
sign, dosages used, use of only Chinese subjects, and duration of observation make 
it difficult to generalize these results to a larger population. Furthermore, the re-
sults may be different in patients compared with healthy volunteers. Relatively 
large SDs were found in the pharmacokinetic parameters.
Table IV. Analysis of adverse events associated with multiple-dose administration of 
rosuvastatin in healthy Chinese volunteers (N = 12).
Relationship to
Dose, Rosuvastatin
Sex mg Event Administration
Female 20 Dizziness, cold sweats Possible
Male 5 Abdominal discomfort Possible
Female 10 Abdominal discomfort, nausea Possible
Female 10 Jaw pain Possible
Female 5 Abdominal discomfort Possible
Female 20 Dizziness, cold sweats Possible
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Table V. Adverse laboratory findings before and after multiple-dose rosuvastatin administration in healthy Chinese volunteers 
(N = 12).
Dose, Poststudy Clinically Clinically
Sex mg Parameter Prestudy Day 7 Day 12* Significant Relevant
Female 5 Direct bilirubin, μmoL/L 6.8 8.2 8.0 No Possible
Male 5 Creatine kinase, U/L   81 242 94 No Possible
Alanine aminotransferase, U/L  10  78 38 No Possible
Male 5 Direct bilirubin, μmoL/L  5.1 8.2 6.4 No Possible
Creatine kinase, U/L 141 307 153 Yes Possible
Female 5 Urinalysis Normal WBC count, Normal No Possible
10–12/hpf
× 109/L
Male 20 Total bilirubin, μmoL/L 22.8 26.4  19 No Possible
Direct bilirubin, μmoL/L   7.0 10.3 7.2 No Possible
Creatine kinase, U/L 152  415 311† Yes Possible
Electrocardiography Normal S/O Normal No Possible
WBC = white blood cell; S/O = suspect of.
*Ninety-six hours after 7 days of rosuvastatin administration.
† Creatine kinase was 189 U/L 12 days after the last dose of rosuvastatin.
403
R. Zhang et al.
CONCLUSIONS
In this small study in healthy Chinese volunteers, rosuvastatin systemic exposure ap-
peared to be dose-proportional over the dosing range of 5 to 20 mg with multiple-
dose administration. There was no accumulation of rosuvastatin in the body with the
5- and 10-mg doses. However, the results suggest that rosuvastatin may have accu-
mulated when the dose was increased to 20 mg. No serious AEs or deaths occurred
with any of the 3 doses studied.
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